Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

CC-122 Rollover Study

This research study, called the 'CC-122 Rollover Study,' is investigating a new medication called CC-122. It's designed for people with certain types of blood cancer, specifically multiple myeloma, follicular lymphoma, and diffuse large B-cell lymphoma. This is an early phase of research, aiming to understand how the medicine behaves in the human body. Researchers will be looking at how the body absorbs, uses, and gets rid of the drug. The goal is to gather important information about the safety and effects of CC-122 as a potential new treatment option for these conditions.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Celgene Corp.

Enrolment target

Start

12 Jun 2023

Multiple Myeloma Follicular Lymphoma Diffuse Large B-Cell Lymphoma.

What is this study about?

This study is called the 'CC-122 Rollover Study' and it's looking at a new medicine named CC-122. It's for people who have certain types of blood cancer, including multiple myeloma, follicular lymphoma, and diffuse large B-cell lymphoma. These are all conditions where specific blood cells don't grow or work properly.

This is a very early stage of research, sometimes called a 'Phase 1' study. At this point, scientists are mostly interested in understanding how the new medicine works in the human body. They want to find out how it's absorbed, how it travels through the body, how the body uses it, and how it's eventually removed. This helps them understand what doses might be safe and how often it should be given.

The main aim of this study is to gather important information about CC-122's safety and how it is processed by the body. This kind of research is a crucial step before a new medicine can be tested on a larger scale to see how well it treats a condition. Findings from studies like this help researchers decide if CC-122 has the potential to become a helpful new treatment option for people with these cancers.

Key takeaways

This study is for adults (18+) with specific blood cancers.
It's an early-stage study for a new medicine called CC-122.
The main goal is to understand how the body handles the medicine.
You would receive the study medication and be closely monitored.
Participation is voluntary, and you can withdraw at any time.
It helps researchers find new potential treatments for these cancers.

Who may be eligible?

To join this study, you need to be at least 18 years old. There's no upper age limit, so adults of all ages can be considered. The study is open to both men and women.

However, it's important to remember that having one of the cancers mentioned (multiple myeloma, follicular lymphoma, or diffuse large B-cell lymphoma) is a key requirement. Other factors about your health and medical history, which aren't listed here, will also be very important. A doctor on the study team would need to check all these details carefully to see if this study is suitable for you.

Even if you meet these basic age and gender requirements, there will be more specific health checks and medical criteria that only a study doctor can assess. It's always best to discuss your individual situation with your own doctor first.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of multiple myeloma, follicular lymphoma, or diffuse large B-cell lymphoma?
Are you able to attend regular study appointments?
Are you willing to consider an experimental treatment?

Answer every question to see your result.

What does participation involve?

Taking part in this study would involve regular visits to a clinic or hospital where the study is taking place. You would likely have various medical assessments, such as blood tests, physical examinations, and possibly other tests to check your health and how the medicine is affecting you. You would be given the study medication, CC-122, according to a specific schedule decided by the researchers. The length of your participation would depend on the study's design and your individual response, but typically early-stage studies involve close monitoring and might last several months. There will be planned follow-up appointments even after you stop taking the medicine to ensure your well-being.

Potential risks and benefits

Potential benefits of joining this study could include receiving a new, experimental treatment for your condition that is not yet widely available. You would also be contributing valuable information that could help others with similar conditions in the future. However, there may be risks involved, as with any new medicine. These could include side effects from the CC-122 medication, which will be carefully monitored. You will have full rights to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France
—
Unverified
Netherlands

Common questions

What is CC-122?

CC-122 is a new investigational medicine being studied for certain blood cancers. Early studies help us learn how it works.

What kind of cancers is this study for?

This study is for people with multiple myeloma, follicular lymphoma, or diffuse large B-cell lymphoma.

Is this medicine available to everyone?

No, CC-122 is an experimental medicine, which means it's only available to people taking part in specific research studies like this one.

Why is this study called 'Phase 1'?

Phase 1 means it's an early study to mostly learn about the safety of the medicine and how it works in the body, rather than how well it treats the cancer yet.

Do I have to pay to be in the study?

Generally, study medications and basic procedures related to the trial are covered by the study sponsor. You should confirm this with the study team.